A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)
A Phase 3b Extension Study of Adjunctive ALKS 5461 in the Treatment of Refractory Major Depressive Disorder
Sponsor: Alkermes, Inc.
Terminated
Sponsor Decision
Other terminated trials from Alkermes, Inc.
- Schizophrenia · Phase PHASE4 · Mar 2025
- Schizoaffective Disorder, Depressive Type · Phase PHASE4 · Oct 2022
- Central Nervous System Diseases · Phase PHASE1 · Aug 2022
- Heroin Dependence · Phase PHASE3 · Dec 2021
- Healthy · Phase PHASE1 · Jan 2020
More terminations from Alkermes, Inc.
A PHASE3 clinical study on Refractory Major Depressive Disorder, this trial is terminated or withdrawn. The trial is conducted by Alkermes, Inc. and has accumulated 10 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Terminated PHASE3
Status: Enrolling By Invitation → Terminated
▶ Show 5 earlier versions
-
Apr 2020 — Jun 2020 [monthly]
Enrolling By Invitation PHASE3
-
May 2019 — Apr 2020 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2018 — May 2019 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2018 — Dec 2018 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Aug 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alkermes, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .